S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
S&P 500   5,096.27
DOW   38,996.39
QQQ   439.00
Pure Storage, Hormel Foods rise; WW International, First Advantage fall, Thursday, 2/29/2024
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Thursday, 2/29/2024
Average long-term US mortgage rises to 6.94% after marking fourth-straight weekly increase
Critical asset just had biggest fall on record (Ad)
Best Buy reports lower 4Q sales and profits as shoppers remain cautious
Grads From This Midwestern School Are More Likely to Start a Billion Dollar Company Than Founders Who Went To Stanford, Harvard, or MIT: Study
Critical asset just had biggest fall on record (Ad)
It's Leap Day, and You're Probably Working — Here's How 'February 29' Affects Your Paycheck
From Hometown Hero to Franchise Partner — 3 Celebrities Collaborating With Their Hometown Brands
NASDAQ:ALRN

Aileron Therapeutics (ALRN) Stock Price, News & Analysis

$4.94
+0.22 (+4.66%)
(As of 02/29/2024 ET)
Today's Range
$4.77
$5.03
50-Day Range
$2.92
$5.94
52-Week Range
$1.01
$6.12
Volume
35,026 shs
Average Volume
41,547 shs
Market Capitalization
$24.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

Aileron Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
82.2% Upside
$9.00 Price Target
Short Interest
Healthy
0.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.96mentions of Aileron Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$758 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($2.01) to ($0.65) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.17 out of 5 stars

Medical Sector

380th out of 957 stocks

Biotechnology Industry

9th out of 35 stocks


ALRN stock logo

About Aileron Therapeutics Stock (NASDAQ:ALRN)

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.

ALRN Stock Price History

ALRN Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Aileron Therapeutics upgraded to Buy from Neutral at Ladenburg
Aileron Therapeutics, Inc. (ALRN)
JonesTrading Keeps Their Hold Rating on Aileron Therapeutics (ALRN)
Cancer drugmaker down to 3 employees after trial failure
alrn.a - | Stock Price & Latest News | Reuters
See More Headlines
Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/12/2021
Today
3/01/2024
Next Earnings (Estimated)
3/18/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ALRN
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+82.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-27,330,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$4.10 per share

Miscellaneous

Free Float
4,613,000
Market Cap
$24.16 million
Optionable
Not Optionable
Beta
2.24
Beginners Guide To Retirement Stocks Cover

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report














ALRN Stock Analysis - Frequently Asked Questions

Should I buy or sell Aileron Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALRN shares.
View ALRN analyst ratings
or view top-rated stocks.

What is Aileron Therapeutics' stock price target for 2024?

1 brokerages have issued 12-month price objectives for Aileron Therapeutics' shares. Their ALRN share price targets range from $9.00 to $9.00. On average, they anticipate the company's stock price to reach $9.00 in the next twelve months. This suggests a possible upside of 82.2% from the stock's current price.
View analysts price targets for ALRN
or view top-rated stocks among Wall Street analysts.

How have ALRN shares performed in 2024?

Aileron Therapeutics' stock was trading at $3.05 at the beginning of 2024. Since then, ALRN stock has increased by 62.0% and is now trading at $4.94.
View the best growth stocks for 2024 here
.

Are investors shorting Aileron Therapeutics?

Aileron Therapeutics saw a decline in short interest in February. As of February 15th, there was short interest totaling 31,200 shares, a decline of 22.6% from the January 31st total of 40,300 shares. Based on an average daily volume of 102,100 shares, the short-interest ratio is currently 0.3 days. Currently, 0.8% of the company's stock are short sold.
View Aileron Therapeutics' Short Interest
.

When is Aileron Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 18th 2024.
View our ALRN earnings forecast
.

How were Aileron Therapeutics' earnings last quarter?

Aileron Therapeutics, Inc. (NASDAQ:ALRN) released its earnings results on Friday, November, 12th. The company reported ($1.40) EPS for the quarter, hitting the consensus estimate of ($1.40).

When did Aileron Therapeutics' stock split?

Aileron Therapeutics shares reverse split on Thursday, November 10th 2022. The 1-20 reverse split was announced on Thursday, November 10th 2022. The number of shares owned by shareholders was adjusted after the market closes on Thursday, November 10th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

What other stocks do shareholders of Aileron Therapeutics own?
When did Aileron Therapeutics IPO?

(ALRN) raised $61 million in an IPO on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies served as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.

Who are Aileron Therapeutics' major shareholders?

Aileron Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Sigma Planning Corp (0.34%) and Texas Capital Bank Wealth Management Services Inc (0.32%).
View institutional ownership trends
.

How do I buy shares of Aileron Therapeutics?

Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ALRN) was last updated on 3/1/2024 by MarketBeat.com Staff